Cibus, Inc.
Moat Score — Cibus, Inc.
Total Moat Score
6 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Cibus's proprietary Rapid Trait Development System uses oligonucleotide-directed mutagenesis to create non-transgenic gene edits, a patented approach that also carries a genuine regulatory-classification advantage (lighter oversight than traditional GMOs) that is difficult for competitors to replicate quickly. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a pre-commercial company still funding operations through partner payments and capital raises, Cibus has no production-cost advantage; it has instead been cutting roughly 49 full-time positions across 2025-2026 to manage cash burn toward a targeted $30 million or less annual usage rate. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | Management's estimate of over $200 million in potential annual royalties from herbicide-tolerant rice traits suggests future pricing power if the technology is commercialized as planned in 2027-2028, but with no current product revenue this is unproven. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Gene-editing trait licensing to seed companies and food ingredient partners carries no network effect between customers. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Once a seed or ingredient partner (such as Procter & Gamble on the biofragrance program) integrates a Cibus trait into its breeding or production pipeline, replacing it involves real multi-year switching costs, though no partner is locked in today given the pre-commercial stage. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | Gene-editing trait development requires specialized regulatory and scientific expertise that limits the number of credible competitors, but larger, better-capitalized agricultural biotech players could still out-invest Cibus in the same trait categories. |